Trial site
Sigmedical Services S.R.L.
- 16running trials
- 9closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Conditions
- Lung cancer11 trials
- Gastric and oesophageal cancer3 trials
- Metastatic breast cancer3 trials
- Deep vein thrombosis and pulmonary embolism2 trials
- Head and neck cancer2 trials
- Bladder cancer1 trial
- Kidney cancer1 trial
- Liver and biliary tract cancer1 trial
- Neuroendocrine tumours1 trial
- Pancreatic cancer1 trial
- Sarcoma1 trial
- Phase
- Phase 319 trials
- Phase 25 trials
- Phase 2/31 trial
- Status
- Completed9 trials
- Recruiting9 trials
- Active, not recruiting6 trials
- Not yet recruiting1 trial
- Lead sponsor
- Merck Sharp & Dohme LLC3 trials
- Arcus Biosciences, Inc.2 trials
- Daiichi Sankyo2 trials
- Glaxosmithkline Research & Development Limited2 trials
- Ribocure Pharmaceuticals AB2 trials
- and 14 more
Running trials
Recruiting
Not yet recruiting
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
Recruiting
Active, not recruiting
Active, not recruiting
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer4 recruiting
- Deep vein thrombosis and pulmonary embolism2 recruiting
- Gastric and oesophageal cancer2 recruiting
- Kidney cancer1 recruiting
- Pancreatic cancer1 recruiting
- Sarcoma1 recruiting
Closed trials
Active, not recruiting
Completed
Active, not recruiting
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Completed
Active, not recruiting
Completed
Recruiting
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Active, not recruiting
Completed
Site data: ClinicalTrials.govUpdated 15 Nov 2026